Henry I. Miller

Robert Wesson Fellow in Scientific Philosophy and Public Policy

Henry I. Miller, MS, MD, is the Robert Wesson Fellow in Scientific Philosophy and Public Policy at the Hoover Institution. His research focuses on public policy toward science and technology, encompassing a number of areas, including pharmaceutical development, genetic engineering in agriculture, models for regulatory reform, and the emergence of new viral diseases.

Miller served for fifteen years at the US Food and Drug Administration (FDA) in a number of posts. He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and thus instrumental in the rapid licensing of human insulin and human growth hormone. Thereafter, he was a special assistant to the FDA commissioner and the founding director of the FDA's Office of Biotechnology. During his government service, Miller participated frequently on various expert and policy panels as a representative of the FDA or the US government. As a government official, Miller received numerous awards and citations.

Since coming to the Hoover Institution, Miller has become well known not only for his contributions to scholarly journals but also for his articles and books that make science, medicine, and technology accessible. His work has been widely published in many languages. Monographs include Policy Controversy in Biotechnology: An Insider's View; To America's Health: A Model for Reform of the Food and Drug Administration; and The Frankenfood Myth: How Protest and Politics Threaten the Biotech Revolution. Barron's selected The Frankenfood Myth as one of the 25 Best Books of 2004. In addition, Miller has published extensively in a wide spectrum of scholarly journals and popular publications worldwide, including The Lancet, Journal of the American Medical Association, Science, the Nature family of journals, Chronicle of Higher Education, Forbes, National Review, Wall Street Journal, New York Times, the Guardian, Defining Ideas, and the Financial Times. He is a regulator contributor to Forbes.com and frequently appears on the nationally syndicated radio programs of John Batchelor and Lars Larson.

Miller was selected by the editors of Nature Biotechnology as one of the people who had made the "most significant contributions" to biotechnology during the previous decade. He serves on numerous editorial boards.

Filter By:



Recent Commentary

Analysis and Commentary

It’s Time To Shine A Light On Regulatory 'Dark Matter'

by Angela Logomasini, Henry I. Millervia National Review
Monday, February 20, 2017

President Donald Trump’s desire to shrink the regulatory state by significantly cutting the number of regulations and their impact is laudable. But it won’t be easy, and it won’t be sufficient, because the federal bureaucracy’s tentacles reach deep into private enterprise through a number of non-regulatory programs and actions that if left in place will continue to hinder economic growth.


Will Genetically Engineered Animals Finally Bring Home The Bacon?

by Henry I. Millervia Forbes
Wednesday, February 15, 2017

It’s unusual for an obscure procedural federal law to attract much attention, especially if it’s 20 years old, but the Congressional Review Act is creating buzz. A game-changer for regulatory reform, it could be a significant stimulus to job creation and economic growth.

Blank Section (Placeholder)Analysis and Commentary

Can Trump Make Bureaucrats Accountable?

by Henry I. Millervia Defining Ideas
Friday, February 10, 2017

Officials deserve protection, but not when they undermine the public interest.

Analysis and Commentary

Scientists' Duplicity And Conflicts Of Interest Distort Regulation And Harm Farmers

by Henry I. Millervia Forbes
Wednesday, February 8, 2017

Scientists prostituting themselves by delivering “bespoke” scientific findings for their corporate sponsors and corrupting the scientific literature is a favorite trope of environmental and anti-industry activists. 

Analysis and Commentary

Trying To Lose Weight? A Calorie Is A Calorie Is A Calorie...Probably

by Mia Zaharna, Henry I. Millervia Forbes
Monday, February 6, 2017

Many New Year’s resolutions involved a new gym membership or at least a commitment to break a sweat frequently, most often in order to lose weight. 


You’d Look Good In Designer Genes

by Henry I. Millervia Wall Street Journal
Tuesday, January 31, 2017

Genetic engineering will soon make commercial bluejean production cheaper than ever.

Blank Section (Placeholder)

Don’t Poor Lives Matter?

by Henry I. Millervia Hoover Digest
Friday, January 27, 2017

Regulation that chokes off investment hits everyone in the pocketbook, but the poor also pay with their health. 

an image

To Modulate Drug Prices, We Need Less Regulation And More Competition

by Henry I. Miller, John Cohrssenvia National Review
Wednesday, January 25, 2017

Allowing drugs in the U.S. that have been approved abroad would greatly help patients, providers, and producers. 

Analysis and Commentary

The Purpose Of The Military Is To Defend The Homeland, Not Promote Wind Turbines

by Henry I. Millervia Forbes
Wednesday, January 25, 2017

“The business of America is business,” President Calvin Coolidge famously said. He might have added that the business of the nation’s military is to defend America—not the promotion of radical environmentalism. (Duh.) 

Analysis and Commentary

Fixing FDA Is Literally A Matter Of Life And Death

by Henry I. Miller, Jeff Stiervia The Hill
Wednesday, January 18, 2017

In a December 60 Minutes interview, House Speaker Paul Ryan spoke of the need for regulatory reform.